• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo.

作者信息

Mallick U, Harmer C, Hackshaw A, Moss L

出版信息

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):159-61. doi: 10.1016/j.clon.2012.01.001. Epub 2012 Feb 7.

DOI:10.1016/j.clon.2012.01.001
PMID:22316618
Abstract
摘要

相似文献

1
Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo.低风险分化型甲状腺癌的碘治疗与否（IoN）：继HiLo之后的下一项英国国家癌症研究网络随机试验
Clin Oncol (R Coll Radiol). 2012 Apr;24(3):159-61. doi: 10.1016/j.clon.2012.01.001. Epub 2012 Feb 7.
2
The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.高剂量与低剂量放射性碘治疗试验：一项多中心随机试验，比较分化型甲状腺癌手术后残余灶消融采用高剂量与低剂量放射性碘治疗，以及是否联合重组人促甲状腺激素的疗效。
Clin Oncol (R Coll Radiol). 2008 Jun;20(5):325-6. doi: 10.1016/j.clon.2008.03.010.
3
Reply to the editorial on the HiLo trial.对关于高-低氧试验的社论的回复。
Clin Oncol (R Coll Radiol). 2009 Feb;21(1):72. doi: 10.1016/j.clon.2008.10.001. Epub 2008 Nov 7.
4
[Ablation of thyroid remnant with 30 mCi 131I in thyroid cancer patients prepared with recombinant human TSH].在使用重组人促甲状腺激素进行预处理的甲状腺癌患者中，用30毫居里的131I消融甲状腺残余组织
Arq Bras Endocrinol Metabol. 2012 Jul;56(5):338-40. doi: 10.1590/s0004-27302012000500011.
5
Low-risk differentiated thyroid carcinoma patients still deserve I-131 remnant ablation after total thyroidectomy.低风险分化型甲状腺癌患者在全甲状腺切除术后仍值得进行碘-131残留消融。
Minerva Chir. 2010 Feb;65(1):95-100.
6
Strategies of radioiodine ablation in patients with low-risk thyroid cancer.低危甲状腺癌患者的碘 131 消融策略。
N Engl J Med. 2012 May 3;366(18):1663-73. doi: 10.1056/NEJMoa1108586.
7
High radioactive iodine uptake despite a fully suppressed TSH in a patient with thyroid cancer.一名甲状腺癌患者尽管促甲状腺激素（TSH）完全被抑制，但仍有高放射性碘摄取。
J Clin Endocrinol Metab. 2011 Mar;96(3):589. doi: 10.1210/jc.2010-2053.
8
Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.低危分化型甲状腺癌患者在放射性碘清甲治疗及重组人促甲状腺激素准备后的临床转归。
Clin Oncol (R Coll Radiol). 2012 Apr;24(3):162-8. doi: 10.1016/j.clon.2011.02.011. Epub 2011 Mar 15.
9
The role of radioactive iodine in the treatment of well-differentiated thyroid cancer.放射性碘在分化型甲状腺癌治疗中的作用。
Surg Oncol Clin N Am. 2006 Jul;15(3):625-38. doi: 10.1016/j.soc.2006.05.007.
10
Radioiodine therapy in differentiated thyroid cancer: a nuclear medicine perspective.分化型甲状腺癌的放射性碘治疗：核医学视角
Clin Oncol (R Coll Radiol). 2010 Aug;22(6):430-7. doi: 10.1016/j.clon.2010.05.003. Epub 2010 May 26.

引用本文的文献

1
Evolving Paradigm in Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Historical Perspectives, Current Practices and Future Directions.分化型甲状腺癌放射性碘治疗的发展范式：历史回顾、当前实践与未来方向
Diagnostics (Basel). 2025 Jun 5;15(11):1438. doi: 10.3390/diagnostics15111438.
2
Follow-up and transition of care for low recurrence risk thyroid cancer patients in Canada.加拿大低复发风险甲状腺癌患者的随访与护理过渡
Eur Thyroid J. 2025 Jun 5;14(3). doi: 10.1530/ETJ-25-0072. Print 2025 Jun 1.
3
Reflections on the 2024 KTA Guideline and the Role of Radioiodine Therapy in Differentiated Thyroid Cancer.
关于2024年KTA指南及放射性碘治疗在分化型甲状腺癌中的作用的思考
Nucl Med Mol Imaging. 2025 Apr;59(2):95-99. doi: 10.1007/s13139-024-00903-z. Epub 2025 Jan 24.
4
Radioactive Iodine Therapy in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-II.分化型甲状腺癌的放射性碘治疗：从核医学角度看韩国甲状腺协会2024年指南总结，第二部分
Nucl Med Mol Imaging. 2025 Feb;59(1):8-26. doi: 10.1007/s13139-024-00886-x. Epub 2024 Nov 1.
5
ASO Author Reflections: Addressing Radioactive Iodine Recommendations in Low-to-Intermediate Risk Papillary Thyroid Cancer.美国甲状腺协会作者反思：应对低至中度风险乳头状甲状腺癌的放射性碘治疗建议
Ann Surg Oncol. 2025 Mar;32(3):1721-1722. doi: 10.1245/s10434-024-16514-z. Epub 2024 Nov 14.
6
Initial results of the INSPIRE clinical trial-investigating radiation dosimetry for differentiated thyroid cancer patients.INSPIRE临床试验的初步结果——针对分化型甲状腺癌患者的放射剂量测定研究。
Front Nucl Med. 2023 May 15;3:964478. doi: 10.3389/fnume.2023.964478. eCollection 2023.
7
Consider or not consider: the unsolved question on the use of radioactive iodine for differentiated thyroid cancer with low to intermediate risk of recurrence.考虑还是不考虑：关于放射性碘在复发风险低至中度的分化型甲状腺癌治疗中的未解决问题。
Endocrine. 2025 Feb;87(2):658-666. doi: 10.1007/s12020-024-04027-4. Epub 2024 Sep 26.
8
Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer - a prospective comparison of long-term outcomes.分化型甲状腺癌患者使用30、60和100毫居里放射性碘进行甲状腺残余组织消融——长期疗效的前瞻性比较
Arch Med Sci. 2020 Aug 3;18(5):1241-1247. doi: 10.5114/aoms.2020.97803. eCollection 2022.
9
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline.儿科分化型甲状腺癌：英国国家临床实践共识指南。
Endocr Relat Cancer. 2022 Sep 7;29(11):G1-G33. doi: 10.1530/ERC-22-0035. Print 2022 Nov 1.
10
A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol.一项多中心、非随机、平行分组、非劣效性研究，旨在比较低-中危甲状腺乳头状癌患者无放射性碘残留消融与残留消融治疗的疗效：MOREthyroid 试验方案。
Endocrinol Metab (Seoul). 2020 Sep;35(3):571-577. doi: 10.3803/EnM.2020.681. Epub 2020 Sep 22.